Samuel Herschkowitz

Since 1982, Dr. Samuel Herschkowitz has been a known leader in the area of biotechnology, healthcare devices, and pharmaceutical development. Until its merger with Acerus Pharmaceuticals, Dr. Herschkowitz served as the Chairman and Chief Executive Officer as well as a founder of Serenity Pharmaceuticals. During his career, which spans four decades, he was a Strategic Advisor for Amarantus BioSciences, Inc., Dov Pharmaceuticals, Perceptive Systems, Theragenics Corporation, T-Cell Sciences, Oncogene Sciences, Crossover Ventures, and Mira Dx. Between 1998 and 2006 he was a founder Chief Technical Officer and Chairman of Delcath Systems, Inc. He then served as Interim Chief Operating Officer of Delcath Systems, Inc. from January 4, 2007, to July 1, 2007, before moving on to a full-time position at Serenity Pharmaceuticals. Earlier in his career, he co-founded Venkol Ventures, a venture capital firm specializing in medical technology investments (1987-2002). Prior to that in 1982, Dr. Herschkowitz was a founder and general partner of Banipal Ventures specializing in investing in startup healthcare technology and pharmaceuticals. Prior to founding Banipal, Dr. Herschkowitz was a founder of Medtech Associates. Medtech was a consulting company specializing in due diligence investigations on behalf of health care investors. In 1988, he founded Receptor Technologies, Inc. that subsequently was purchased by Senetek, PLC in 1995. From 1995 until 1998 he was a director of Senetek, PLC, a health care company on the London exchange. Dr. Herschkowitz is a Clinical Professor at PANY, an affiliate of New York University Medical Center. He is Board Certified in Psychiatry and Neurology. He received his medical degree with honors from Downstate Medical Center College of Medicine in 1976.